EVOMEDIS LAUNCHES FIRST CLINICAL TRIAL IN COLLABORATION WITH MEDICAL UNIVERSITY OF GRAZ
Study Aims to Establish Protocol for New Keratinocyte-Based Therapeutics
Graz, 2024 – EVOMEDIS has announced the start of its first clinical trial in cooperation with the Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery, Medical University of Graz. The trial is led by Principal Investigator Univ.-Prof. Dr. Lars-Peter Kamolz, MSc.
The study, titled “Evaluation of isolation and in vitro cultivation of keratinocytes from skin samples - A pilot study” ethic comity number 35-185 ex 22/23, will investigate the isolation and cultivation of skin cells (keratinocytes) from male volunteers. Its goal is to define parameters like volunteer age and body region for sampling in order to isolate keratinocytes best suited for cell-based therapeutics.
Ultimately, this research seeks to define the fundamental requirements for applying these cells in treatments for patients with burns or other skin defects. The study will enroll 20 healthy male subjects between the ages of 18 and 50.
About EVOMEDIS
EVOMEDIS develops innovative cell therapies and medical technology solutions for the treatment of complex burn and chronic wounds. The company combines scientific excellence, practical product development, and state-of-the-art production technologies. Its mission is to provide patients with new, effective treatment options and to make a lasting contribution to improving wound care.